Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64:1167 74. S10.7-4. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392 7. S10.7-5. Kannankeril P, Roden DM, Darbar D, Drug-induced long QT syn- drome. Pharmacol Rev. 2010;62:760 81. S10.7-6. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149 54. S10.7-7. Yang T, Roden DM, Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use- dependence. Circulation. 1996;93:407 11. S10.7-8. Hellestrand KJ, Burnett PJ, Milne JR, et al. Effect of the antiarrhyth- mic agent flecainide acetate on acute and chronic pacing thresh- olds. Pacing Clin Electrophysiol. 1983;6:892 9. S10.7-9. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhyth- mic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation. 1989;79:1106 17. S10.7-10. Schwartz PJ, Woosley RL, Predicting the unpredictable: drug- induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67:1639 50. S10.7-11. Hauptman PJ, Kelly RA, Digitalis. Circulation. 1999;99:1265 70. S10.7-12. Kelly RA, Smith TW, Recognition and management of digitalis toxic- ity. Am J Cardiol. 1992;69:108G 18G. S10.7-13. Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin Electrophysiol. 2012;35:804 10. S10.7-14. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e385 484. S10.7-15. Behr ER, Ritchie MD, Tanaka T, et al. 